2 Cancer Stocks That Could Make You Filthy Rich
The COVID-19 pandemic has done a number on global stock markets this year. Several multibillion-dollar industries, such as airlines, cruise ships, and upscale sit-in restaurants, among many others, are fighting for their very survival right now.
Pharmaceutical companies, especially those specializing in cancer treatments, are a different story altogether, though. While airlines and cruise ships may struggle to regain their footing in the months ahead, cancer companies should quickly get back to business as usual post-pandemic. Most cancer patients, after all, aren't likely to skip out on life-saving treatments unless they absolutely have to. So, once the COVID-19 threat fades, cancer stocks should be among the first to truly rebound.
Which cancer stocks are poised for the biggest gains at the end of this global pandemic? Exelixis (NASDAQ: EXEL) and Immunomedics, Inc. (NASDAQ: IMMU) could both generate enormous levels of free cash flow and top-line growth over the next five to 10 years. In fact, these two cancer specialists might even be able to make their current shareholders filthy rich by the end of the decade. Here's how.
Source Fool.com
